Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC".

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Oct 15;93(21). pii: e00968-19. doi: 10.1128/JVI.00968-19. Print 2019 Nov 1. No abstract available.

2.

Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence.

Lorente E, Barriga A, Barnea E, Palomo C, García-Arriaza J, Mir C, Esteban M, Admon A, López D.

PLoS Negl Trop Dis. 2019 Jul 5;13(7):e0007547. doi: 10.1371/journal.pntd.0007547. eCollection 2019 Jul.

3.

Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.

Marín MQ, Pérez P, Ljungberg K, Sorzano CÓS, Gómez CE, Liljeström P, Esteban M, García-Arriaza J.

J Virol. 2019 Mar 21;93(7). pii: e00055-19. doi: 10.1128/JVI.00055-19. Print 2019 Apr 1.

4.

Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells.

Lorente E, Martín-Galiano AJ, Barnea E, Barriga A, Palomo C, García-Arriaza J, Mir C, Lauzurica P, Esteban M, Admon A, López D.

J Proteome Res. 2019 Mar 1;18(3):900-911. doi: 10.1021/acs.jproteome.8b00595. Epub 2019 Jan 22.

PMID:
30629447
5.

A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice.

Pérez P, Q Marín M, Lázaro-Frías A, Jiménez de Oya N, Blázquez AB, Escribano-Romero E, S Sorzano CÓ, Ortego J, Saiz JC, Esteban M, Martín-Acebes MA, García-Arriaza J.

Sci Rep. 2018 Nov 26;8(1):17385. doi: 10.1038/s41598-018-35724-6.

6.

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Jan 17;93(3). pii: e01513-18. doi: 10.1128/JVI.01513-18. Print 2019 Feb 1. Erratum in: J Virol. 2019 Oct 15;93(21):.

7.

DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost.

Öhlund P, García-Arriaza J, Zusinaite E, Szurgot I, Männik A, Kraus A, Ustav M, Merits A, Esteban M, Liljeström P, Ljungberg K.

Sci Rep. 2018 Aug 20;8(1):12459. doi: 10.1038/s41598-018-31003-6.

8.

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.

Marín MQ, Pérez P, Gómez CE, Sorzano CÓS, Esteban M, García-Arriaza J.

Viruses. 2018 Aug 8;10(8). pii: E414. doi: 10.3390/v10080414.

9.

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, de Quirós JCLB, García F, Plana M; RISVAC02boost study.

PLoS One. 2018 Apr 10;13(4):e0195915. doi: 10.1371/journal.pone.0195915. eCollection 2018.

10.

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Lázaro-Frías A, Gómez-Medina S, Sánchez-Sampedro L, Ljungberg K, Ustav M, Liljeström P, Muñoz-Fontela C, Esteban M, García-Arriaza J.

J Virol. 2018 May 14;92(11). pii: e00363-18. doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.

11.

Complex antigen presentation pathway for an HLA-A*0201-restricted epitope from Chikungunya 6K protein.

Lorente E, Barriga A, García-Arriaza J, Lemonnier FA, Esteban M, López D.

PLoS Negl Trop Dis. 2017 Oct 30;11(10):e0006036. doi: 10.1371/journal.pntd.0006036. eCollection 2017 Oct.

12.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.

Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, Plana M; RISVAC02boost study.

PLoS One. 2017 Oct 24;12(10):e0186602. doi: 10.1371/journal.pone.0186602. eCollection 2017. Erratum in: PLoS One. 2018 Apr 10;13(4):e0195915.

13.

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.

Roques P, Ljungberg K, Kümmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, Hallengärd D, García-Arriaza J, Meinke A, Esteban M, Merits A, Le Grand R, Liljeström P.

JCI Insight. 2017 Mar 23;2(6):e83527. doi: 10.1172/jci.insight.83527.

14.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M.

J Virol. 2017 Apr 13;91(9). pii: e02182-16. doi: 10.1128/JVI.02182-16. Print 2017 May 1.

15.

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.

Gómez CE, Perdiguero B, García-Arriaza J, Cepeda V, Sánchez-Sorzano CÓ, Mothe B, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, López Bernaldo de Quirós JC, Brander C, García F, Esteban M.

PLoS One. 2015 Nov 6;10(11):e0141456. doi: 10.1371/journal.pone.0141456. eCollection 2015.

16.

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.

Vijayan A, García-Arriaza J, Raman SC, Conesa JJ, Chichón FJ, Santiago C, Sorzano CÓ, Carrascosa JL, Esteban M.

PLoS One. 2015 Jul 24;10(7):e0133595. doi: 10.1371/journal.pone.0133595. eCollection 2015.

17.

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, Yates NL, Shen X, Tomaras GD, Ferrari G, Foulds KE, McDermott A, Kao SF, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Wagner R, Ding S, Pantaleo G, Esteban M.

J Virol. 2015 Aug;89(16):8525-39. doi: 10.1128/JVI.01265-15. Epub 2015 Jun 3.

18.

The evolution of poxvirus vaccines.

Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M.

Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726. Review.

19.

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group.

J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26.

PMID:
25724985
20.

Enhancing poxvirus vectors vaccine immunogenicity.

García-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2014;10(8):2235-44. doi: 10.4161/hv.28974. Review.

21.

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M.

J Virol. 2015 Jan 15;89(2):970-88. doi: 10.1128/JVI.02469-14. Epub 2014 Oct 29.

22.

Prime-boost immunization strategies against Chikungunya virus.

Hallengärd D, Lum FM, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LF, Esteban M, Liljeström P.

J Virol. 2014 Nov;88(22):13333-43. doi: 10.1128/JVI.01926-14. Epub 2014 Sep 10.

23.

Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.

Knudsen ML, Ljungberg K, Kakoulidou M, Kostic L, Hallengärd D, García-Arriaza J, Merits A, Esteban M, Liljeström P.

J Virol. 2014 Nov;88(21):12438-51. doi: 10.1128/JVI.02223-14. Epub 2014 Aug 13.

24.

Exploration of sequence space as the basis of viral RNA genome segmentation.

Moreno E, Ojosnegros S, García-Arriaza J, Escarmís C, Domingo E, Perales C.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):6678-83. doi: 10.1073/pnas.1323136111. Epub 2014 Apr 22.

25.

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M.

J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8.

26.

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

García-Arriaza J, Gómez CE, Sorzano CÓ, Esteban M.

J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3.

27.

Clinical applications of attenuated MVA poxvirus strain.

Gómez CE, Perdiguero B, García-Arriaza J, Esteban M.

Expert Rev Vaccines. 2013 Dec;12(12):1395-416. doi: 10.1586/14760584.2013.845531. Epub 2013 Oct 30. Review.

PMID:
24168097
28.

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.

García-Arriaza J, Arnáez P, Gómez CE, Sorzano CÓ, Esteban M.

PLoS One. 2013 Jun 27;8(6):e66894. doi: 10.1371/journal.pone.0066894. Print 2013.

29.

High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.

Gómez CE, Perdiguero B, Cepeda MV, Mingorance L, García-Arriaza J, Vandermeeren A, Sorzano CÓ, Esteban M.

J Virol. 2013 Jul;87(13):7282-300. doi: 10.1128/JVI.03246-12. Epub 2013 Apr 17.

30.

Poxvirus vectors as HIV/AIDS vaccines in humans.

Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2012 Sep;8(9):1192-207. doi: 10.4161/hv.20778. Epub 2012 Aug 21. Review.

31.

Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.

García-Arriaza J, Arnáez P, Jiménez JL, Gómez CE, Muñoz-Fernández MÁ, Esteban M.

Virus Res. 2012 Aug;167(2):391-6. doi: 10.1016/j.virusres.2012.05.020. Epub 2012 May 30.

PMID:
22659488
32.

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.

García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M.

PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.

33.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M.

Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9.

PMID:
21907749
34.

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M.

J Virol. 2011 Nov;85(21):11468-78. doi: 10.1128/JVI.05165-11. Epub 2011 Aug 24.

35.

Viral genome segmentation can result from a trade-off between genetic content and particle stability.

Ojosnegros S, García-Arriaza J, Escarmís C, Manrubia SC, Perales C, Arias A, Mateu MG, Domingo E.

PLoS Genet. 2011 Mar;7(3):e1001344. doi: 10.1371/journal.pgen.1001344. Epub 2011 Mar 17.

36.

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.

García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M.

PLoS One. 2010 Aug 24;5(8):e12395. doi: 10.1371/journal.pone.0012395.

37.

Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M.

PLoS One. 2010 Jun 30;5(6):e11406. doi: 10.1371/journal.pone.0011406.

38.

New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines.

Rodríguez-Calvo T, Ojosnegros S, Sanz-Ramos M, García-Arriaza J, Escarmís C, Domingo E, Sevilla N.

PLoS One. 2010 Apr 29;5(4):e10414. doi: 10.1371/journal.pone.0010414.

39.

Characterization of minority subpopulations in the mutant spectrum of HIV-1 quasispecies by successive specific amplifications.

García-Arriaza J, Domingo E, Briones C.

Virus Res. 2007 Nov;129(2):123-34. Epub 2007 Aug 16.

PMID:
17706828
40.

Molecular basis for a lack of correlation between viral fitness and cell killing capacity.

Herrera M, García-Arriaza J, Pariente N, Escarmís C, Domingo E.

PLoS Pathog. 2007 Apr;3(4):e53.

41.

Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes.

García-Arriaza J, Ojosnegros S, Dávila M, Domingo E, Escarmís C.

J Mol Biol. 2006 Jul 14;360(3):558-72. Epub 2006 May 24.

PMID:
16797586
42.

Viruses as quasispecies: biological implications.

Domingo E, Martin V, Perales C, Grande-Pérez A, García-Arriaza J, Arias A.

Curr Top Microbiol Immunol. 2006;299:51-82. Review.

PMID:
16568896
43.
44.

Evolutionary transition toward defective RNAs that are infectious by complementation.

García-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarmís C.

J Virol. 2004 Nov;78(21):11678-85.

Supplemental Content

Loading ...
Support Center